Immediate Start of ART for HIV May Impact 10-Year Risk for Cancer
For people with HIV, deferral of antiretroviral therapy has a small effect on increasing the 10-year risk for cancer.
For people with HIV, deferral of antiretroviral therapy has a small effect on increasing the 10-year risk for cancer.
Infusion of a broadly neutralizing antibody does not prevent overall HIV-1 acquisition more effectively than placebo.
White matter hyperintensities may be more common in patients living with HIV, even if well-controlled, and may correlate with other clinical parameters.
According to this systematic review, sexual and gender minority patients may be at risk for several neurologic deficiencies.
In HIV-infected adults, lower CD4+ T-cell counts were associated with smaller hippocampal and thalamic brain volumes regardless of treatment status.
A new point-of-care lateral flow assay featured the same sensitivity as mycobacterial culture in detecting tuberculosis meningitis in adults with HIV.
People with HIV, particularly patients in sub-Saharan Africa and Latin America, have a high burden of HIV-associated neurocognitive disorder.
Excess mortality occurred as the result of a number of causes, including overdose, injuries, and both infectious and noncommunicable diseases.
Neurologic conditions associated with HIV remain major contributors to morbidity and mortality, and are increasingly recognized in the aging population of individuals living with HIV.
Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.